RxDoctor Payments Data

Philip Scheel, MD

Family Medicine · Redway, CANPI 1922053305

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 60 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$851
  • Pfizer$215
  • Lilly USA, LLC$135
  • Bayer$126
  • Esperion Therapeutics, Inc.$64
  • Merck$63
  • plus $137 from 7 others

What the payments were for

  • Food & beverage$1,58299%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,591 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$268
Medicare patients
30
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$63,421
JardianceEmpagliflozin46$58,277
EliquisApixaban52$50,041
MounjaroTirzepatide47$49,949
RybelsusSemaglutide18$42,022
TrulicityDulaglutide29$41,444
OzempicSemaglutide39$40,381
InvokanaCanagliflozin21$29,585
NexletolBempedoic Acid28$23,385
XareltoRivaroxaban15$22,380
BelsomraSuvorexant50$21,334
Incruse ElliptaUmeclidinium Bromide39$20,851
Spiriva RespimatTiotropium Bromide25$12,763
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,457
Breo ElliptaFluticasone/Vilanterol30$12,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$135$91,39376 claims
Novo NordiskRybelsus, Ozempic$851$82,40357 claims
Johnson & JohnsonInvokana, Xarelto$16$51,96536 claims
PfizerEliquis$215$50,04152 claims
Esperion Therapeutics, Inc.Nexletol$64$23,38528 claims
MerckBelsomra$63$21,33450 claims
BayerKerendia$126$10,51811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Redway

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →